<DOC>
	<DOCNO>NCT00222443</DOCNO>
	<brief_summary>Determine toxicity maximum tolerate dose escalate daily protract irinotecan , weekly vincristine , temozolomide vantin ; evaluate feasibility repetitive cycle chemotherapy estimate response rate combination child adolescents recurrent solid tumor lymphomas .</brief_summary>
	<brief_title>Pilot Study Combining Temozolomide , Oncovin , Camptosar Oral Antibiotic Children Adolescents With Recurrent Malignancy</brief_title>
	<detailed_description>Determine toxicity maximum tolerate dose escalate daily protract irinotecan , weekly vincristine , temozolomide vantin ; evaluate feasibility repetitive cycle chemotherapy estimate response rate combination child adolescents recurrent solid tumor lymphomas . Temozolomide give mouth one hour prior daily irinotecan dose day 1-5 cycle . 100 mg/m2/day . Irinotecan give IV dose escalation ( minimum 3 6 patient per cohort ) start 15 mg/m2/day daily 5 day 2 week . Vincristin give IV 1.5 mg/m2/dose ( max dose 2mg ) day 1 8 cycle . Vantin give 10 mg/kg/day divide 2 oral dos ( max dose 400 mg/day ) start 48 hour prior start treatment cycle continue 48 hour last irinotecan dose . Cycle repeat every 28 day . Therapy continue minimum two cycle unless progression disease unacceptable toxicity may continue long patient tolerates therapy continued disease control one year therapy .</detailed_description>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>Under age 21 year time study entry Malignant solid tumor , include CNS tumor lymphomas Recurrent refractory disease amenable potentially curative therapy At least three week since last myelosuppressive chemotherapy &gt; 6 month allogeneic stem cell transplant Adequate renal hepatic function Adequate peripheral blood count unless bone marrow involve Patients leukemia eligible Patients uncontrolled infection exclude Patients receive 4 prior chemotherapy Patients receive P450 enzymeinducing anticonvulsant Patients receive cancer chemotherapy investigational agent Possible pregnancy exclude</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Recurrent solid tumor</keyword>
	<keyword>recurrent lymphoma</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Adolescents</keyword>
</DOC>